Stockscreener 앱 받기
72.91
0.73%
0.345
전일 마감가:
$72.56
열려 있는:
$72.73
하루 거래량:
11,203
Relative Volume:
0.02
시가총액:
$3.10B
수익:
$451.36M
순이익/손실:
$-66.42M
주가수익비율:
-45.29
EPS:
-1.6097
순현금흐름:
$-22.31M
1주 성능:
+4.13%
1개월 성능:
+7.55%
6개월 성능:
+3.91%
1년 성능:
+57.42%
1일 변동 폭
$70.92
$73.26
1주일 범위
$67.94
$73.33
52주 변동 폭
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
명칭
Tarsus Pharmaceuticals Inc
전화
(949) 409-9820
주소
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
72.91 | 3.09B | 451.36M | -66.42M | -22.31M | -1.6097 |
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.00 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.33 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.48 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.76 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-11-20 | 개시 | Mizuho | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-27 | 재개 | H.C. Wainwright | Buy |
| 2023-11-20 | 개시 | Goldman | Neutral |
| 2023-07-18 | 개시 | William Blair | Outperform |
| 2023-05-18 | 개시 | Guggenheim | Buy |
| 2022-08-01 | 개시 | Barclays | Overweight |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-23 | 개시 | Oppenheimer | Outperform |
| 2020-11-10 | 개시 | BofA Securities | Buy |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Ladenburg Thalmann | Buy |
| 2020-11-10 | 개시 | Raymond James | Strong Buy |
모두보기
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Published on: 2026-04-13 13:14:16 - baoquankhu1.vn
(TARS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tarsus to receive $15M milestone after China approves TP-03 eye therapy - MSN
Published on: 2026-04-08 15:20:10 - baoquankhu1.vn
Aug Rallies: Can Tarsus Pharmaceuticals Inc benefit from deglobalization2026 Update & Stepwise Trade Signal Guides - baoquankhu1.vn
Analyst Calls: Is Tarsus Pharmaceuticals Inc still a buy after recent gains2026 Market Trends & Low Risk High Reward Ideas - baoquankhu1.vn
Capricorn Fund Managers Ltd Decreases Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following First Dosing In TP-05 Lyme Trial - Sahm
Tarsus Pharmaceuticals, Inc. (TARS) stock price, news, quote and history - Yahoo Finance UK
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street Zen - MarketBeat
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN) - The Globe and Mail
JPMorgan Chase & Co. Sells 63,420 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins - Sahm
How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors - Yahoo Finance
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Price-Driven Insight from (TARS) for Rule-Based Strategy - Stock Traders Daily
TARS Technical Analysis & Stock Price Forecast - Intellectia AI
Tarsus Pharmaceuticals (TARS) Initiates Phase 2 Trial for Lyme D - GuruFocus
Tarsus Pharmaceuticals, Inc. recently disclosed the latest progress on its leading vaccine candidate under development for Lyme disease. - Bitget
Biopharmaceutical company Tarsus Pharmaceuticals, Inc. announced that its innovative oral tablet TP-05 (lotilaner) for the potential prevention of Lyme disease has dosed the first subject in the Phase 2 clinical trial "Calliope". - Bitget
Tarsus Doses First Participant in Calliope, A Phase 2 - GlobeNewswire
First patient dosed in 700-person study to prevent Lyme disease - Stock Titan
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Published on: 2026-03-30 08:36:12 - baoquankhu1.vn
How China TP-03 Approval and US$15 Million Milestone Could Shape Tarsus Pharmaceuticals (TARS) Investors - Sahm
Vanguard Realignment: Tarsus (NASDAQ: TARS) Ownership Reported as 0% by Parent - Stock Titan
Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS) - The Globe and Mail
Q2 EPS Estimate for Tarsus Pharmaceuticals Lifted by Analyst - MarketBeat
Mizuho raises Tarsus Pharmaceuticals stock price target on China approval By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A. - marketbeat.com
Can Tarsus Pharmaceuticals Inc maintain sales growth2026 Setups & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - AOL.com
Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade - Stock Titan
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - The Motley Fool
Tarsus earns $15M milestone on China approval of eye drug By Investing.com - Investing.com South Africa
Tarsus earns $15M milestone on China approval of eye drug - Investing.com Canada
William Blair reiterates Outperform on Tarsus Pharmaceuticals stock By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals shares rise on China drug approval milestone By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals (TARS) Reaches $15M Milestone After TP-03 Approval in China - GuruFocus
Tarsus Pharmaceuticals Achieves $15 Million Milestone Payment Following Regulatory Approval of TP-03 in China - Quiver Quantitative
China clears first Demodex blepharitis treatment for 40 million people - Stock Titan
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus - Bitget
LifeSci Capital Remains a Buy on Tarsus Pharmaceuticals (TARS) - The Globe and Mail
TARS SEC FilingsTarsus Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
(TARS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) - msn.com
Seshadri Neervannan to sell TARS shares (NASDAQ: TARS) — March dispositions listed - Stock Titan
Tarsus Pharmaceuticals Insider Sold Shares Worth $2,364,904, According to a Recent SEC Filing - marketscreener.com
Tarsus Pharmaceuticals Insider Sold Shares Worth $892,528, According to a Recent SEC Filing - marketscreener.com
Tarsus Pharmaceuticals Insider Sold Shares Worth $772,444, According to a Recent SEC Filing - MarketScreener
Tarsus Pharmaceuticals Inc (TARS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.62%
자본화:
|
볼륨(24시간):